Heart failure & cardiomyopathies
Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial
Study context
- Population
- Patients hospitalised for acute HF with dyspnoea, volume overload and elevated natriuretic peptide, at high risk (eGFR <60 mL/min/1.73 m², furosemide ≥40 mg daily before admission, or urine output <300 mL within 2 hours after IV furosemide)planned
- Participants
- 500 patients
- Planned comparison
- Empagliflozin vs placebo
- Primary endpoint
- Win ratio for hierarchical composite:
- Death within 90 days
- HF rehospitalisation within 90 days
- Worsening HF during hospitalisation
- Urine output within 48 hours after treatment initiation
Methodological detailsdesign paper, double-blind, placebo-controlled, multicentre, 47 sites in Japan, 1:1 randomisation
- Design paper
- Double-blind
- Placebo-controlled
- Multicentre
- 47 sites in Japan
- 1:1 randomisation
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: Rationale for and design of the EMPA-AHF trial. Am Heart J. Published 8 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →